NCT04050553View on ClinicalTrials.gov

A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

February 24, 2020

Primary Completion Date

January 25, 2022

Study Completion Date

January 25, 2022

Conditions
Diabetes Mellitus, Type 2Hypoglycemia
Interventions
DRUG

Tirzepatide

Administered SC

DRUG

Placebo

Administered SC

Trial Locations (1)

8036

Universitätsklinikum Graz, Graz

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT04050553 - A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter